柴胡舒肝丸与依折麦布联合治疗非酒精性脂肪性肝病的效果分析

Effect of Chaihu Shugan Pill Combined with Ezetimibe in the Treatment of Non-alcoholic Fatty Liver Disease

目的探讨柴胡舒肝丸联合依折麦布治疗非酒精性脂肪性肝病的临床疗效与安全性。方法回顾性选取2022年6月—2023年6月西南医科大学附属中医医院收治的120例非酒精性脂肪性肝病患者的临床资料。根据治疗方法的不同将患者分为两组,每组60例。西医组采用依折麦布治疗,联合组采用依折麦布联合柴胡舒肝丸治疗。对比两组肝功能、血脂水平、不良反应总发生率。结果治疗后,联合组丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆红素水平均低于西医组,差异有统计学意义(P均<0.05)。治疗后,联合组总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平均低于西医组,差异有统计学意义(P均<0.05)。联合组不良反应总发生率为5.00%(3/60),低于西医组的16.67%(10/60),差异有统计学意义(χ^(2)=4.227,P<0.05)。结论相较于单独使用依折麦布,联合柴胡舒肝丸治疗非酒精性脂肪性肝病的临床疗效更优,能够显著改善肝功能及血脂水平,且有较高的安全性。

Objective To explore the clinical efficacy and safety of Chaihu Shugan Pill combined with ezetimibe in the treatment of non-alcoholic fatty liver disease.Methods The clinical data of 120 patients with nonalcoholic fatty liver disease admitted to the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University from June 2022 to June 2023 were retrospectively selected.According to different treatment methods,the patients were divided into two groups,60 cases in each group.The Western medicine group was treated with ezetimibe,and the combined group was treated with ezetimibe combined Chaihu Shugan Pill.The liver function,blood lipid levels and the total incidence of adverse reactions were compared between the two groups.Results After treatment,the alanine aminotransferase,aspartate aminotransferase,total bilirubin levels of the combined group were lower than those of the Western medicine group,and the differences were statistically significant(all P<0.05).After treatment,the total cholesterol,triglyceride,low density lipoprotein cholesterol levels of the combined group were lower than those of the Western medicine group,and the differences were statistically significant(all P<0.05).The total incidence of adverse reactions in the combined group was 5.00%(3/60),which was lower than 16.67%(10/60)in the Western medicine group,and the difference was statistically significant(χ^(2)=4.227,P<0.05).Conclusion Compared with ezetimibe alone,combined with Chaihu Shugan Pill has better clinical efficacy in the treatment of non-alcoholic fatty liver disease,can significantly improve liver function and lipid levels,and has higher security.